Journal of Rare Cardiovascular Diseases

ISSN: 2299-3711 (Print) | e-ISSN: 2300-5505 (Online)

The clinical outcomes from administration of angiotensin receptor-neprilysin inhibitor in heart failure patients and reduced ejection fraction: A sample from Iraqi cardiac centers

Zainab Abbass Hassan Manshad1, Nagham Yahya Ghafil2
1Al-Hussein Teaching Hospital, Thi-Qar Health Directorate, Iraq
2Faculty of Pharmacy, Kufa University, Iraq
Zainab Abbass Hassan Manshad1, Nagham Yahya Ghafil2
1Al-Hussein Teaching Hospital, Thi-Qar Health Directorate, Iraq
2Faculty of Pharmacy, Kufa University, Iraq
Corresponding Email: zainaba.alzirjawi@student.uokufa.edu.iq
  • Received 09/06/2024
  • Revised 10/08/2024
  • Accepted 30/12/2024
  • Published 24/02/2025

Full Text:

PDF
Abstract

Background: Treatment choices for heart failure vary depending on the type of heart failure and are related to the unique characteristics of each patient. The three main goals are to limit or prevent hospitalization, improve symptoms and functional capacity, and reduce mortality. Despite the latest advancements in treatment techniques for patients with heart failure with reduced ejection fraction, the prognosis remains poor and leads to harmful short- and long-term outcomes, even when symptoms improve with standard medications. Sacubitril/valsartan is a novel pharmacological therapy for heart failure with reduced ejection fraction. It is an effective medication that improves cardiac structure and function, reduces hospitalizations, and enhances the overall quality of life in patients with heart failure with reduced ejection fraction. When administered early in the course of the disease at appropriate doses, it lowers the incidence of adverse cardiovascular events and, consequently, readmission rates. Aim of Study: To evaluate the clinical outcomes following the administration of the sacubitril/valsartan combination in a sample of patients previously diagnosed with heart failure and reduced ejection fraction. Patients and Methods: This interventional trial was conducted over a seven-month period on patients with heart failure and reduced ejection fraction who were treated at one of the Cardiac Centers in Iraq. Each patient received two months of follow-up. Results: There was a significant decrease in the key biomarkers related to heart failure, accompanied by an improvement in the overall clinical state. Conclusions: The use of the sacubitril/valsartan combination in Iraqi heart failure patients yielded satisfactory clinical results.

key word
sacubitril/valsartan combination, heart failure with reduced ejection fraction

References

  1. Buda, Valentina, et al. “An up-to-date article regarding particularities of drug treatment in patients with chronic heart failure.” Journal of Clinical Medicine 11.7 (2022): 2020.
  2. Cabral, Joana, et al. “Sacubitril/valsartan in everyday clinical practice: an observational study based on the experience of a heart failure clinic.” Cardiovascular Diagnosis and Therapy 11.6 (2021): 1217-1227.
  3. Damman, Kevin, et al. “Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure.” JACC: Heart Failure 6.6 (2018): 489-498.
  4. El‐Battrawy, Ibrahim, et al. “The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.” ESC Heart Failure 10.2 (2023): 943-954.
  5. Hu, Tianyang, Yiting Liu, and Yake Lou. “Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis.” Frontiers in Pharmacology 14 (2023): 925375.
  6. Proudfoot, Clare, et al. “Real-world effectiveness and safety of sacubitril/valsartan in heart failure: a systematic review.” International Journal of Cardiology 331 (2021): 164-171.
  7. Sasmita, Bryan Richard, et al. “Edema index predicts mortality in patients with chronic heart failure: a prospective, observational study.” Global Heart 19.1 (2024): 5.
  8. Zhang, Mingsong, et al. “The history and mystery of sacubitril/valsartan: From clinical trial to the real world.” Frontiers in Cardiovascular Medicine 10 (2023): 1102521.
  9. Zhang, Rui, et al. “The efficacy and safety of sacubitril/valsartan in heart failure patients: a review.” Journal of Cardiovascular Pharmacology and Therapeutics 27 (2022): 10742484211058681.
  10. Margiana, Ria, et al. “Functions and therapeutic interventions of non-coding RNAs associated with TLR signaling pathway in atherosclerosis.” Cellular Signalling 100 (2022): 110471.
  11. Arif, Anam, et al. “The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer.” International Immunopharmacology 114 (2023): 109581.
  12. Lei, Zimeng, et al. “Detection of abemaciclib, an anti-breast cancer agent, using a new electrochemical DNA biosensor.” Frontiers in Chemistry 10 (2022): 980162.
  13. Lafta, Holya A., et al. “Tumor-associated macrophages (TAMs) in cancer resistance; modulation by natural products.” Current Topics in Medicinal Chemistry 23.12 (2023): 1104-1122.
  14. Hjazi, Ahmed, et al. “The pathological role of CXC chemokine receptor type 4 (CXCR4) in colorectal cancer (CRC) progression; special focus on molecular mechanisms and possible therapeutics.” Pathology-Research and Practice 248 (2023): 154616.
  15. Hjazi, Ahmed, et al. “Unraveling the impact of 27-hydroxycholesterol in autoimmune diseases: Exploring promising therapeutic approaches.” Pathology-Research and Practice 248 (2023): 154737.
  16. Gupta, Jitendra, et al. “Double-edged sword role of miRNA-633 and miRNA-181 in human cancers.” Pathology-Research and Practice 248 (2023): 154701.
  17. Sane, Shahryar, et al. “Investigating the effect of pregabalin on postoperative pain in non-emergency craniotomy.” Clinical Neurology and Neurosurgery 226 (2023): 107599.
  18. Farhan, Shireen Hamid, et al. “Exosomal non-coding RNA derived from mesenchymal stem cells (MSCs) in autoimmune diseases progression and therapy; an updated review.” Cell Biochemistry and Biophysics 82.4 (2024): 3091-3108.
  19. Qasim, Maytham T., and Zainab I. Mohammed. “The Association of Helicobacter pylori Infection and Virulence Factors in Gastric Cancer in Thi-Qar, Iraq.” Asian Pacific Journal of Cancer Biology 9.4 (2024): 541-545.
  20. Zamanian, Mohammad Yasin, et al. “Effects of resveratrol on nonmelanoma skin cancer (nmsc): a comprehensive review.” Food Science & Nutrition 12.11 (2024): 8825-8845.
  21. Hsu, Chou-Yi, et al. “MicroRNA-enriched exosome as dazzling dancer between cancer and immune cells.” Journal of Physiology and Biochemistry 80.4 (2024): 811-829.
  22. Lv, Jing, et al. “A comprehensive immunobiology review of IBD: With a specific glance to Th22 lymphocytes development, biology, function, and role in IBD.” International Immunopharmacology 137 (2024): 112486.
  23. Ul Hassan Shah, Zameer, et al. “Development of antihyperlipidemic drug loaded β-CD-based microparticulate carrier systems: tuning and optimization.” Polymer-Plastics Technology and Materials 63.11 (2024): 1438-1463.
  24. Hsu, Chou-Yi, et al. “A comprehensive insight into the contribution of epigenetics in male infertility; focusing on immunological modifications.” Journal of Reproductive Immunology (2024): 104274.
  25. Qasim, M. T., M. N. Fenjan, and H. A. Thijail. “Molecular identification of cystoisospora belli in patients infected with the virus human immunodeficiency.” International Journal of Drug Delivery Technology 12.2 (2022): 701-704.
  26. Qasim, M. T., et al. “Ovine pasteurellosis vaccine: assessment of the protective antibody titer and recognition of the prevailing serotypes.” Archives of Razi Institute 77.3 (2022): 1207.
  27. Qasim, Maytham T., and Zainab I. Mohammed. “Investigating treatment response and viral immunity in early rheumatoid arthritis via immune response profiling.” Journal of Rare Cardiovascular Diseases 4.8 (2024): 166-173.
  28. Patel, Ayyub Ali, et al. “Application of mesenchymal stem cells derived from the umbilical cord or Wharton’s jelly and their extracellular vesicles in the treatment of various diseases.” Tissue and Cell (2024): 102415.
  29. Zamanian, Mohammad Yasin, et al. “Chemopreventive and Anticancer Role of Resveratrol against non-melanoma skin cancer (NMSC): Focusing on cellular and molecular mechanisms and biochemistry.” ESS Open Archive Eprints 979 (2024): 97976792.
  30. Fakhrioliaei, Azadeh, et al. “Potential Role of Nrf2, HER2, and ALDH in Cancer Stem Cells: A Narrative Review.” The Journal of Membrane Biology 257.1 (2024): 3-16.
  31. Ramaiah, Pushpamala, et al. “Dietary polyphenols and the risk of metabolic syndrome: a systematic review and meta-analysis.” BMC Endocrine Disorders 24.1 (2024): 26-39.
  32. Al-Hawary, Sulieman Ibraheem Shelash, et al. “Tumor-derived lncRNAs: Behind-the-scenes mediators that modulate the immune system and play a role in cancer pathogenesis.” Pathology-Research and Practice 254 (2024): 155123.
Journal Help

Indexation

Scopus
ICV: 116.28
MNiSW: 20
Polish Medical Bibliography
Search all articles by
RCD Classification
User
Username:
Password:
Remember
Keywords
Classification of Rare Cardiovascular Diseases anticoagulation atrial fibrillation atrial septal defect cardiac tumor cardiomyopathy computed tomography congenital heart disease echocardiography electrocardiogram electrocardiography heart failure implantable cardioverter‑defibrillator magnetic resonance imaging pregnancy pulmonary arterial hypertension pulmonary hypertension rare cardiovascular disease rare disease right heart catheterization right ventricular failure
Journal Content
Search
Browse
Copyright © 2025 Journal of Rare Cardiovascular Diseases